参考文献
1: Prados-Frutos JC, Rojo R, González-Serrano J, González-Serrano C, Sammartino
G, Martínez-González JM, Sánchez-Monescillo A. Phentolamine mesylate to reverse
oral soft-tissue local anesthesia: A systematic review and meta-analysis. J Am
Dent Assoc. 2015 Oct;146(10):751-9.e3. doi: 10.1016/j.adaj.2015.04.018. Review.
PubMed PMID: 26409985.
2: Grover HS, Gupta A, Saksena N, Saini N. Phentolamine mesylate: It's role as a
reversal agent for unwarranted prolonged local analgesia. J Indian Soc Pedod Prev
Dent. 2015 Oct-Dec;33(4):265-8. doi: 10.4103/0970-4388.165646. PubMed PMID:
26381625.
3: Boynes SG, Riley AE, Milbee S, Bastin MR, Price ME, Ladson A. Evaluating
complications of local anesthesia administration and reversal with phentolamine
mesylate in a portable pediatric dental clinic. Gen Dent. 2013 Aug;61(5):70-6.
PubMed PMID: 23928444.
4: Nourbakhsh N, Shirani F, Babaei M. Effect of phentolamine mesylate on duration
of soft tissue local anesthesia in children. J Res Pharm Pract. 2012
Oct;1(2):55-9. doi: 10.4103/2279-042X.108371. PubMed PMID: 24991590; PubMed
Central PMCID: PMC4076863.
5: Yagiela JA. What's new with phentolamine mesylate: a reversal agent for local
anaesthesia? SAAD Dig. 2011 Jan;27:3-7. Review. PubMed PMID: 21323030.
6: Hersh EV, Lindemeyer RG. Phentolamine mesylate for accelerating recovery from
lip and tongue anesthesia. Dent Clin North Am. 2010 Oct;54(4):631-42. doi:
10.1016/j.cden.2010.06.004. Review. PubMed PMID: 20831927.
7: Froum SJ, Froum SH, Malamed SF. The use of phentolamine mesylate to evaluate
mandibular nerve damage following implant placement. Compend Contin Educ Dent.
2010 Sep;31(7):520, 522-8. PubMed PMID: 20879205.
8: Wynn RL. Phentolamine mesylate--an old medical drug becomes a new dental drug.
Gen Dent. 2009 May-Jun;57(3):200-2. PubMed PMID: 19819806.
9: Rutherford B, Zeller JR, Thake D. Local and systemic toxicity of intraoral
submucosal injections of phentolamine mesylate (OraVerse). Anesth Prog. 2009
Winter;56(4):123-7. doi: 10.2344/0003-3006-56.4.123. PubMed PMID: 20020792;
PubMed Central PMCID: PMC2796381.
10: Tavares M, Goodson JM, Studen-Pavlovich D, Yagiela JA, Navalta LA, Rogy S,
Rutherford B, Gordon S, Papas AS; Soft Tissue Anesthesia Reversal Group. Reversal
of soft-tissue local anesthesia with phentolamine mesylate in pediatric patients.
J Am Dent Assoc. 2008 Aug;139(8):1095-104. Erratum in: J Am Dent Assoc. 2008
Oct;139(10):1312. PubMed PMID: 18682624.
11: Poulet FM, Berardi MR, Halliwell W, Hartman B, Auletta C, Bolte H.
Development of hibernomas in rats dosed with phentolamine mesylate during the
24-month carcinogenicity study. Toxicol Pathol. 2004 Sep-Oct;32(5):558-66. PubMed
PMID: 15603540.
12: Padma-Nathan H, Goldstein I, Klimberg I, Coogan C, Auerbach S, Lammers P;
Vasomax Study Group. Long-term safety and efficacy of oral phentolamine mesylate
(Vasomax) in men with mild to moderate erectile dysfunction. Int J Impot Res.
2002 Aug;14(4):266-70. PubMed PMID: 12152116.
13: Lammers PI, Rubio-Aurioles E, Castell R, Castaneda J, Ponce de Leon R, Hurley
D, Lipezker M, Loehr LA, Lowrey F. Combination therapy for erectile dysfunction:
a randomized, double blind, unblinded active-controlled, cross-over study of the
pharmacodynamics and safety of combined oral formulations of apomorphine
hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with
moderate to severe erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):54-9;
discussion 60. PubMed PMID: 11896479.
14: Dinsmore WW, Gingell C, Hackett G, Kell P, Savage D, Oakes R, Frentz GD.
Treating men with predominantly nonpsychogenic erectile dysfunction with
intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a
novel auto-injector system: a multicentre double-blind placebo-controlled study.
BJU Int. 1999 Feb;83(3):274-9. PubMed PMID: 10233493.
15: McCleane GJ. Intravenous phentolamine mesylate alleviates the pain of
pancreatic carcinoma. Pain. 1997 Nov;73(2):263-4. PubMed PMID: 9415515.
16: McCleane GJ. Phentolamine mesylate can alleviate the nausea and vomiting
associated with liver metastasis. Ulster Med J. 1996 Nov;65(2):165-6. PubMed
PMID: 8979787; PubMed Central PMCID: PMC2448593.
17: McCleane GJ. Oral phentolamine mesylate in the treatment of complex regional
pain syndrome. Ulster Med J. 1996 May;65(1):87-8. PubMed PMID: 8686109; PubMed
Central PMCID: PMC2448742.
18: Hadzija BW, Mattocks AM, Stahl GM. Physicochemical stability of papaverine
hydrochloride-phentolamine mesylate mixtures used for intracavernous injection: a
preliminary evaluation. J Urol. 1988 Jul;140(1):64-5. PubMed PMID: 2454330.
19: Tu YH, Allen LV Jr, Wang DP. Stability of papaverine hydrochloride and
phentolamine mesylate in injectable mixtures. Am J Hosp Pharm. 1987
Nov;44(11):2524-7. PubMed PMID: 2446497.
20: Okabe S, Takeuchi K, Honda K, Takagi K. Effects of phentolamine mesylate and
propranolol hydrochloride on aspirin-induced gastric lesions and gastric
secretions in the rat. Jpn J Pharmacol. 1974 Jun;24(3):490-2. PubMed PMID:
4449157.
